iTeos Therapeutics Stock - Analyst consensus and biotech sector check

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:26 CET. Details in the imprint.

iTeos Therapeutics (US46572C1009) is trading on the Nasdaq on Friday without a fresh company-specific announcement. The stock therefore hinges on existing analyst expectations and the current mood in the biotech sector, which has been mixed in recent weeks.

How analysts currently rate iTeos

According to data compiled by MarketBeat, iTeos Therapeutics stock carries a consensus rating of "Hold" from Wall Street analysts, with an average price target of about $10.75 per share. Individual targets span a relatively narrow range around that level.

The stock trades in a 52-week range between roughly $6.18 and $11.35, putting the consensus target slightly above the midpoint of the past year’s trading corridor. Against this backdrop, the market appears to be waiting for new clinical or partnering news before rerating the shares.

Biotech peers and weekly backdrop

iTeos is part of the US biotech universe focused on oncology, a segment that has seen alternating risk appetite in recent weeks as investors balance rate-cut hopes with clinical and regulatory risks. The wider biotech cohort on the Nasdaq has moved unevenly, with stock-specific trial readouts driving many of the bigger swings.

Compared with larger immuno-oncology names that already generate product revenue, iTeos remains a clinical-stage story and therefore trades more on trial milestones and partnership updates than on quarterly earnings trends. All told, this keeps the stock firmly in the high-risk, high-uncertainty bracket of the sector.

How the company makes its money

iTeos Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapies designed to enhance the anti-tumor activity of the immune system. Its pipeline centers on antibody-based and small-molecule drug candidates that target key pathways in the tumor microenvironment, with the aim of improving cancer treatment outcomes over time.

Where the stock trades today

The shares of iTeos Therapeutics (US46572C1009) trade on the Nasdaq at $10.16 as of 06/19/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.